Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Disease Progression × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 276 Neoplasm Metastasis 34 Ovarian Neoplasms 18 Neoplasms 18 Advanced Breast Cancer 17 Endometrial Neoplasms 11 Prostatic Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Hereditary Sensory and Autonomic Neuropathies 8 Triple Negative Breast Neoplasms 5 Breast Cancer Metastatic 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Neoplasms by Site 4 Multiple Endocrine Neoplasia Type 1 4 Colorectal Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Breast Diseases 4 Small Cell Lung Carcinoma 3 Pancreatic Neoplasms 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Stomach Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Liposarcoma 2 Hyperglycemia 2

Interventions

Lenalidomide 4 Dexamethasone 4 Cyclophosphamide 4 Bortezomib 4 Cisplatin 3 Carboplatin 3 vandetanib 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 pomalidomide 2 pembrolizumab 2 liposomal doxorubicin 2 fludarabine 2 durvalumab 2 capivasertib 2 Paclitaxel 2 Nivolumab 2 Gemcitabine 2 Doxorubicin 2 Bevacizumab 2 venetoclax 1 umbralisib 1 ublituximab 1 tremelimumab 1 tivozanib 1 ricolinostat 1 pazopanib 1 niraparib 1 nilotinib 1 marizomib 1 lutetium Lu 177 dotatate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06635447 2026-01-13

CAPItrue

AstraZeneca

Phase 3 Recruiting

Breast Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡